How the New Vaccine Works
The technology behind Canine Melanoma Vaccine, DNA is very complicated — but the results are very simple.
Conventional vaccines (for other common diseases) stimulate an immune response directed against foreign proteins. Tyrosinase, a protein present on canine melanoma cells, is not usually targeted by the dog’s immune system because it also is present on normal canine cells.
Canine Melanoma Vaccine, DNA trains the immune system to recognize this cancer-associated protein as a threat to the dog’s health.1,2,3
Canine Melanoma Vaccine, DNA is produced with a non-canine gene for tyrosinase inserted in a small ring of DNA. This foreign tyrosinase is different enough from canine tyrosinase to break through the dog’s tolerance of a self-tumor, so it induces a strong and active immune response.1
Using the immune system, in addition to surgery and/or radiation therapy (after removing the initial tumor with surgery and/or radiation therapy), may help extend the survival time of the dog with oral melanoma.1,2
NOTICE: The USDA has issued a conditional U.S. Veterinary Biological Product License for this therapeutic vaccine. This conditional license is a response to an application and assurance of safety and purity, and a reasonable expectation of efficacy based on initial trials.1,2During this period of conditional license, additional research will be conducted to further support the safety and efficacy of the vaccine. Production under this license is in compliance with all regulations and standards applicable to such products.
1Bergman PJ, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006;24:4582-4585.
More Info 1
No, it is to be used as a “therapeutic vaccine,” meaning that it is an immunotherapy for use after the tumor has been treated with surgery and/or radiation therapy.
Definitely not. It is used after melanoma has been locally controlled with surgery and/or radiation.
Read the answers to the most commonly asked questions about this new vaccine.